Sanofi | SNY - Pre Tax Profit


Sanofi reported EUR2B in Pre-Tax Profit for its fiscal quarter ending in March of 2026.





Pre Tax Profit Change Date
AbbVie USD 5.57B 2.9B Mar/2026
Amgen USD 1.51B 2.41B Dec/2025
AstraZeneca USD 3.91B 1.28B Mar/2026
Bristol-Myers Squibb USD 1.47B 1.64B Dec/2025
Canopy Growth CAD -157.96M 95.71M Mar/2026
Corcept Therapeutics USD 9.91M 5.33M Dec/2025
Drreddys Laboratories INR 2B 13.43B Mar/2026
Eli Lilly USD 8.27B 1.03B Dec/2025
Genmab DKK 55M 427M Dec/2025
GlaxoSmithKline GBP 2.14B 919M Mar/2026
Glaxosmithkline GBP 2.14B 312M Mar/2026
J&J USD 8.66B 839M Jun/2026
Lakefront Biotherapeutics EUR 13.96M 769.2M Mar/2026
Merck USD 3.42B 3.32B Dec/2025
Novartis USD 3.84B 802M Mar/2026
Novartis USD 3.84B 1.33B Mar/2026
Pacira USD 571K 8.95M Dec/2025
Perrigo USD -1.33B 1.35B Dec/2025
Pfizer USD 5.18B 6.82B Mar/2026
Phibro Animal Health USD 38.62M 1.26M Dec/2025
Prestige Brands USD 61.81M 7.32M Dec/2025
Roche Holding CHF 4.79B 3.01B Jun/2025
Sanofi EUR -1.16B 5.5B Dec/2025
Sanofi EUR 2B 3.16B Mar/2026
Supernus Pharmaceuticals USD -5.95M 4.04M Mar/2026
UCB EUR 789M 427M Jun/2025
Zoetis USD 761M 126M Dec/2025